Complete Regimen Tablet Gets FDA Approval for HIV

According to the Public Health Agency of Canada, in 2014, there were 2,570 new HIV infections reported in Canada, with 54.3 per cent (1,396) of the cases occurring among MSM and 23.2 per cent among females. Last week, Canada and Israel approved tenofovir/emtricitabine for PrEP, joining France, South Africa, and Kenya.

"In New Zealand parallel importing generic medications is legal; however, people need to be very careful that they are using PrEP in ways that are safe for them and the community". "This means the doctor has to take full responsibility for any problems that arise from the use of the medication". "The late adopters don't know what an iPhone is".

While daily PrEP is capable of providing significant HIV protection for most people, clinicians maintain that the prevention method isn't foolproof.

PrEP is known to be ineffective when taken sporadically.

The treatment is designed for patients who are aged 12 years or older, have no antiretroviral treatment history, and have HIV-1 RNA levels ≤100,000 copies/mL.

Testing for HIV before starting the drug. The man began the PrEP regimen in April 2013 following a recommendation.

TAF is administered in a lower dose compared with TDF and reduces the amount of tenofovir in the bloodstream by 90%, the release said. The same blood sample showed adequate levels of the drugs in Truvada, as did a dried blood spot test used to estimate drug levels over the past several weeks.

This first documented case of apparent PrEP failure spurred much news coverage and discussion at the conference, with experts agreeing that it does not call into question the high effectiveness of PrEP. Those considered at high risk may have a partner who is HIV positive, or they could be engaging in "risky" behaviour such as unprotected sex with partners who may be exposed to HIV or sharing injection needles, Bogoch said. Large PrEP programs like those at Kaiser in San Francisco and the San Francisco AIDS Foundation's Strut center have also seen no new infections among people taking PrEP consistently.

The approval is based on the results of clinical trials that assessed the safety, efficacy and tolerability of rilpivirine-based therapy administered as R/F/Viread (tenofovir disoproxil fumarate, Gilead Sciences; TDF) and R plus F/TDF, and F/TAF-based therapy administered as Genvoya (elvitegravir/cobicistat/emtricitabine/TAF, Gilead Sciences; E/C/F/TAF) in various HIV-positive populations including treatment-naive adults and adolescents and virologically suppressed adults with or without mild-to-moderate renal impairment who switched from protease inhibitor-, non-nucleoside reverse-transcriptase inhibitor-, and integrase strand-transfer inhibitor-based regimens. "PrEP protection is extremely high, even if it is not 100 percent".

Source: Complete Regimen Tablet Gets FDA Approval for HIV